Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the languages menu
  5. Go to the help menu
  6. Go to the modules
  7. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Canadian Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Media Room

Contact us

Sanofi Canada

2905 Place Louis-R.-Renaud
Laval, Quebec, H7V 0A3

Media inquiries

514-856-3860
Toll-free: 1-877-904-2667

Catherine Cunningham

Manager, Corporate and
Brand Communications
514-956-6120

General inquiries

514-956-6200
1-800-363-6364

Press Releases

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

2010200920082007

Oct 17, 2017

Favourable results from a scientific study conducted by Canadian investigators on the dosage adjustment of Toujeo® LAVAL, QC, Oct. 17, 2017 /CNW Telbec/ - Individuals with type 2 diabetes may...

More
Oct 17, 2017

Favourable results from a scientific study conducted by Canadian investigators on the dosage adjustment of Toujeo® LAVAL, QC, Oct. 17, 2017 /CNW Telbec/ - Individuals with type 2 diabetes may...

More
May 29, 2017

Employees not as happy with health benefits as past years & are more willing to give access to personal data MONTREAL, May 29, 2017 /CNW Telbec/ - The 20th anniversary of The Sanofi Canada...

More
May 12, 2017

The Connecting Nurses Patient Centricity program is proud to announce that Guillaume Fontaine, a Montreal-based graduate student and registered nurse, will be a recipient of the 2017 Global...

More
Apr 7, 2017

Laval, Quebec (April 7, 2017) — Sanofi Canada announces, all new and existing Canadian patients prescribed Renagel® or Renvela®, will have access to RenassistPLUS, a patient support and...

More
Jan 27, 2017
Sanofi Canada Recognized as One of Canada’s Top R&D Investors

Montreal, Quebec – January 26, 2017 – Sanofi Canada is pleased to announce that it ranks among Canada’s Top 100 Corporate Research and Development (R&D) Spenders, according to a new report...

More
May 26, 2016

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -

More
May 24, 2016

As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have accessto PRALUENT™ MONTREAL, May 24, 2016 /CNW Telbec/ - Sanofi Canada is pleased to...

More
May 9, 2016

Iveta Demirova, 16, student at New Westminster Secondary School in British Columbia, Recognized for Novel HIV-1 Treatment OTTAWA, May 9, 2016 /CNW Telbec/ - Iveta Demirova from New Westminster...

More
Feb 23, 2016

Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the License and Development Agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of Auvi-Q® and Allerject®...

More
 

Corporate information

CORPORATE INFORMATION